Low-Dose Dasiglucagon Versus Oral Glucose for Prevention of Insulin-Induced Hypoglycemia in People With Type 1 Diabetes: A Phase 2, Randomized, Three-Arm Crossover Study.

Laugesen C, Ranjan AG, Schmidt S, Nørgaard K

Diabetes care1 Jun 2022Cited by 9 (Europe PMC)

PMID35475907DOI10.2337/dc21-2304PepBankPUB-35475907

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 1 diabetes, hypoglycemia occurred in 5 after dasiglucagon versus 10 after oral glucose (P = 0.096).
In plain wordsDasiglucagon produced numerically fewer hypoglycemia cases than oral glucose, without a significant difference.
Peptide
Dasiglucagon
Outcome
No significant changeHypoglycemia occurrence
Study
n = 20
Comparator
15 g oral glucose
Outcome group
Glycemic control · Metabolic and weight
Studied dose
80 µg · subcutaneousAs given in this study (human).
Measurements
Participants with hypoglycemia
5 participants
80 µg dasiglucagon (D80)
Participants with hypoglycemia
10 participants
15 g oral glucose (CHO)
Source sentences
Summary
Hypoglycemia (<3.9 mmol/L [70 mg/dL]) occurred in 10 participants after CHO, in 5 after D80, and in 4 after D120 (CHO vs. D80, P = 0.096; CHO vs. D120, P = 0.034).
2 context sentences(design, population, supporting numbers)
Summary · context
Twenty adults with type 1 diabetes using multiple daily injection or insulin pump therapy completed a phase 2, randomized, three-arm crossover study.
Summary · context
When a PG concentration of 4.5 mmol/L (81 mg/dL) was reached, 15 g oral glucose (CHO) from dextrose tablets, 80 µg dasiglucagon (D80), or 120 µg dasiglucagon (D120) was administered.
Report a problemFND-3547590701
02HumanRandomized controlled trialEfficacy outcome
In adults with type 1 diabetes, hypoglycemia occurred in 4 after dasiglucagon versus 10 after oral glucose (P = 0.034).
In plain wordsDasiglucagon reduced hypoglycemia occurrence compared with oral glucose.
Peptide
Dasiglucagon
Outcome
DecreaseHypoglycemia occurrence
Study
n = 20
Comparator
15 g oral glucose
Outcome group
Glycemic control · Metabolic and weight
Studied dose
120 µg · subcutaneousAs given in this study (human).
Measurements
Participants with hypoglycemia
4 participants
120 µg dasiglucagon (D120)
Participants with hypoglycemia
10 participants
15 g oral glucose (CHO)
Source sentences
Summary
Hypoglycemia (<3.9 mmol/L [70 mg/dL]) occurred in 10 participants after CHO, in 5 after D80, and in 4 after D120 (CHO vs. D80, P = 0.096; CHO vs. D120, P = 0.034).
2 context sentences(design, population, supporting numbers)
Summary · context
Twenty adults with type 1 diabetes using multiple daily injection or insulin pump therapy completed a phase 2, randomized, three-arm crossover study.
Summary · context
When a PG concentration of 4.5 mmol/L (81 mg/dL) was reached, 15 g oral glucose (CHO) from dextrose tablets, 80 µg dasiglucagon (D80), or 120 µg dasiglucagon (D120) was administered.
Report a problemFND-3547590702
03HumanRandomized controlled trialEfficacy outcome
Time in hypoglycemia was 7% after dasiglucagon versus 14% after oral glucose, with no significant overall difference (P = 0.273).
In plain wordsTime in hypoglycemia did not differ significantly across interventions.
Peptide
Dasiglucagon
Outcome
No significant changeTime in hypoglycemia
Study
n = 20
Comparator
15 g oral glucose
Outcome group
Glycemic control · Metabolic and weight
Studied dose
80 µg · subcutaneousAs given in this study (human).
Measurements
Time in hypoglycemia
7%
80 µg dasiglucagon (D80)
Time in hypoglycemia
14%
15 g oral glucose (CHO)
Source sentences
Summary
Time spent in hypoglycemia (<3.9 mmol/L [70 mg/dL]) was 14%, 7%, and 6% for CHO, D80, and D120, respectively (P = 0.273).
2 context sentences(design, population, supporting numbers)
Summary · context
Twenty adults with type 1 diabetes using multiple daily injection or insulin pump therapy completed a phase 2, randomized, three-arm crossover study.
Summary · context
When a PG concentration of 4.5 mmol/L (81 mg/dL) was reached, 15 g oral glucose (CHO) from dextrose tablets, 80 µg dasiglucagon (D80), or 120 µg dasiglucagon (D120) was administered.
Report a problemFND-3547590703
04HumanRandomized controlled trialEfficacy outcome
Time in hypoglycemia was 6% after dasiglucagon versus 14% after oral glucose, with no significant overall difference (P = 0.273).
In plain wordsTime in hypoglycemia did not differ significantly across interventions.
Peptide
Dasiglucagon
Outcome
No significant changeTime in hypoglycemia
Study
n = 20
Comparator
15 g oral glucose
Outcome group
Glycemic control · Metabolic and weight
Studied dose
120 µg · subcutaneousAs given in this study (human).
Measurements
Time in hypoglycemia
6%
120 µg dasiglucagon (D120)
Time in hypoglycemia
14%
15 g oral glucose (CHO)
Source sentences
Summary
Time spent in hypoglycemia (<3.9 mmol/L [70 mg/dL]) was 14%, 7%, and 6% for CHO, D80, and D120, respectively (P = 0.273).
2 context sentences(design, population, supporting numbers)
Summary · context
Twenty adults with type 1 diabetes using multiple daily injection or insulin pump therapy completed a phase 2, randomized, three-arm crossover study.
Summary · context
When a PG concentration of 4.5 mmol/L (81 mg/dL) was reached, 15 g oral glucose (CHO) from dextrose tablets, 80 µg dasiglucagon (D80), or 120 µg dasiglucagon (D120) was administered.
Report a problemFND-3547590704
05HumanRandomized controlled trialEfficacy outcome
Median time to a glucose increase of 1.1 mmol/L was 15 (95% CI 15-20) minutes after dasiglucagon versus 30 (25-50) after oral glucose (P = 0.006).
In plain wordsDasiglucagon raised glucose faster than oral glucose.
Peptide
Dasiglucagon
Outcome
DecreaseTime to glucose increase
Study
n = 20
Comparator
15 g oral glucose
Outcome group
Glycemic control · Metabolic and weight
Studied dose
80 µg · subcutaneousAs given in this study (human).
Measurements
Median time to PG increase of 1.1 mmol/L
15 minutes
80 µg dasiglucagon (D80)
95% CI
15 to 20 minutes
80 µg dasiglucagon (D80), median time
Median time to PG increase of 1.1 mmol/L
30 minutes
15 g oral glucose (CHO)
95% CI
25 to 50 minutes
15 g oral glucose (CHO), median time
Source sentences
Summary
The median time (95% CI) from intervention to first increase in PG of 1.1 mmol/L (20 mg/dL) was 30 (25-50), 15 (15-20), and 15 (15-20) minutes for CHO, D80, and D120, respectively (CHO vs. D80, P = 0.006; CHO vs. D120, P = 0.003).
2 context sentences(design, population, supporting numbers)
Summary · context
Twenty adults with type 1 diabetes using multiple daily injection or insulin pump therapy completed a phase 2, randomized, three-arm crossover study.
Summary · context
When a PG concentration of 4.5 mmol/L (81 mg/dL) was reached, 15 g oral glucose (CHO) from dextrose tablets, 80 µg dasiglucagon (D80), or 120 µg dasiglucagon (D120) was administered.
Report a problemFND-3547590705
06HumanRandomized controlled trialEfficacy outcome
Median time to a first 1.1 mmol/L glucose increase was 15 (95% CI 15-20) minutes after both 80 µg and 120 µg dasiglucagon versus 30 (25-50) minutes after oral glucose (CHO vs. D80, P = 0.006; CHO vs. D120, P = 0.003).
In plain wordsDasiglucagon raised glucose faster than oral glucose.
Peptide
Dasiglucagon
Outcome
DecreaseTime to glucose increase
Study
n = 20
Comparator
15 g oral glucose
Outcome group
Glycemic control · Metabolic and weight
Studied dose
80 or 120 µg · subcutaneousAs given in this study (human).
Measurements
Median time to first PG increase of 1.1 mmol/L
30 minutes
15 g oral glucose; 95% CI 25-50
Median time to first PG increase of 1.1 mmol/L
15 minutes
80 µg dasiglucagon; 95% CI 15-20
Median time to first PG increase of 1.1 mmol/L
15 minutes
120 µg dasiglucagon; 95% CI 15-20
Source sentences
Summary
The median time (95% CI) from intervention to first increase in PG of 1.1 mmol/L (20 mg/dL) was 30 (25-50), 15 (15-20), and 15 (15-20) minutes for CHO, D80, and D120, respectively (CHO vs. D80, P = 0.006; CHO vs. D120, P = 0.003).
2 context sentences(design, population, supporting numbers)
Summary · context
Twenty adults with type 1 diabetes using multiple daily injection or insulin pump therapy completed a phase 2, randomized, three-arm crossover study.
Summary · context
When a PG concentration of 4.5 mmol/L (81 mg/dL) was reached, 15 g oral glucose (CHO) from dextrose tablets, 80 µg dasiglucagon (D80), or 120 µg dasiglucagon (D120) was administered.
Report a problemFND-3547590706
07HumanRandomized controlled trialSafety outcome
Nausea episodes were numerically higher after dasiglucagon than oral glucose, without a significant difference.
In plain wordsNausea was numerically more frequent with dasiglucagon than oral glucose, without a significant difference.
Peptide
Dasiglucagon
Outcome
No significant changeNausea
Study
n = 20
Comparator
15 g oral glucose
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
80 or 120 µg · subcutaneousAs given in this study (human).
Source sentences
Summary
Episodes of nausea were numerically, but not significantly, higher after dasiglucagon administration.
2 context sentences(design, population, supporting numbers)
Summary · context
Twenty adults with type 1 diabetes using multiple daily injection or insulin pump therapy completed a phase 2, randomized, three-arm crossover study.
Summary · context
When a PG concentration of 4.5 mmol/L (81 mg/dL) was reached, 15 g oral glucose (CHO) from dextrose tablets, 80 µg dasiglucagon (D80), or 120 µg dasiglucagon (D120) was administered.
Report a problemFND-3547590707
08HumanRandomized controlled trialSafety outcome
Visual analog scale-assessed adverse effects did not differ significantly between dasiglucagon and oral glucose interventions.
In plain wordsReported adverse effects did not differ significantly between dasiglucagon and oral glucose.
Peptide
Dasiglucagon
Outcome
No significant changeVisual analog scale adverse effects
Study
n = 20
Comparator
15 g oral glucose
Outcome group
Adverse events · Whole body
Studied dose
80 or 120 µg · subcutaneousAs given in this study (human).
Source sentences
Summary
No significant differences in visual analog scale-assessed adverse effects were observed between interventions.
2 context sentences(design, population, supporting numbers)
Summary · context
Twenty adults with type 1 diabetes using multiple daily injection or insulin pump therapy completed a phase 2, randomized, three-arm crossover study.
Summary · context
When a PG concentration of 4.5 mmol/L (81 mg/dL) was reached, 15 g oral glucose (CHO) from dextrose tablets, 80 µg dasiglucagon (D80), or 120 µg dasiglucagon (D120) was administered.
Report a problemFND-3547590708

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 2 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedNot applicableNCT06082973

Dual-hormone Artificial Pancreas Versus Single-hormone Under Exercise and a Meal Challenge

Universitat Politècnica de Valèncian = 1515 May 2024 to 30 May 2025

Type 1 Diabetes

Trial page ClinicalTrials.govUpdated 18 Dec 2025

CompletedPhase 2NCT04449692

Low-dose Dasiglucagon for Prevention of Insulin-Induced Hypoglycemia in People With Type 1 Diabetes

Steno Diabetes Center Copenhagenn = 202 Jul 2020 to 4 Jan 2021

Type 1 Diabetes · Hypoglycemia

Trial page ClinicalTrials.govUpdated 9 Feb 2021

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.